Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunovaccine and IRX Therapeutics have signed a preclinical research collaboration to evaluate the combination of IRX's primary cell-derived biologic, IRX-2, and DepoVax-based therapeutic cancer vaccines.
Subscribe to our email newsletter
Immunovaccine’s DepoVax platform is a lipid depot-based vaccine delivery technology.
The primary cell-derived biologic, IRX-2, designed to restore the immune system, seeks to overcome cancer-induced immune suppression and restore anti-tumor response, vital steps in successfully treating cancer.
The research aims to show that the combination of two technologies generates a superior anti-tumor immune response and will provide the foundation for the development of therapeutic cancer vaccines.
IRX Therapeutics chief scientific officer Neil Berinstein said that the pre-clinical studies have already shown that IRX-2 can enhance immune response triggered by peptide and other cancer vaccine platforms and there is reason to believe that this would be further enhanced by combining IRX-2 with Immunovaccine’s DepoVax-immune adjuvant platform.
Immunovaccine Research and Development vice president Marc Mansour said that IRX-2 has interesting immune-modulating characteristics and they hope that combining it with DepoVax-based anti-cancer vaccines, the result would be a synergistic anti-tumor effect.